Dyslipidaemia

28 registered clinical trials studyying Dyslipidaemia — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Comparative Effects of Carnivore and Mediterranean-style Diets on LDL Aggregation and Cardiometabolic Health NCT07462871	Liverpool John Moores University	N/A
Not Yet Recruiting	Associations Between Dietary Patterns, LDL Aggregation, and Cardiometabolic Health: A Cross-sectional Analysis NCT07474233	Liverpool John Moores University	—
Recruiting	A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density L NCT07218900	AstraZeneca	Phase 2
Recruiting	OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbiditie NCT06890169	Changi General Hospital	N/A
Enrolling By Invitation	Effect of Mediterranean Diet Combined With Intermittent Fasting on Liver Fibrosis Compared to Naltrexone/Bupro NCT06845345	Carmen Dietvorst	Phase 4
Recruiting	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia NCT06834932	AstraZeneca	Phase 2 / Phase 3
Completed	An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated NCT06671405	AstraZeneca	Phase 1
Completed	Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome NCT07497776	National Institute of Kidney Disease and Urology (NIKDU)	Phase 4
Completed	A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High L NCT05979428	Novo Nordisk A/S	Phase 1
Completed	A Study of AZD8233 in Participants With Dyslipidemia NCT04641299	AstraZeneca	Phase 2
Completed	Evaluation of Food Supplementation in Subjects With Suboptimal Levels of LDL Cholesterol NCT07492264	Cooper Consumer Health	N/A
Completed	Bioequivalence Study of Capsule and Tablet Formulations of TA-8995 NCT02523391	Xention Ltd	Phase 1
Withdrawn	Effect of Nasal CPAP on Lipid Profile in Patients With Dyslipidaemia and Sleep Apnea NCT02557412	Hospital Universitario La Paz	N/A
Recruiting	The European NAFLD Registry NCT04442334	Newcastle University	—
Completed	CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II) NCT02230241	AstraZeneca	—
Completed	Study of the Electrocardiographic Effects of TA-8995 NCT02241759	Xention Ltd	Phase 1
Completed	Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients NCT01632358	Novartis Pharmaceuticals	Phase 1
Completed	Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol NCT01451918	University Health Network, Toronto	Phase 2
Unknown	A Multi-site, Individually Randomized, Controlled Translation Trial of Integrated and Comprehensive Care Strat NCT01212328	Public Health Foundation of India	N/A
Completed	Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia NCT01221584	AstraZeneca	—
Completed	Statin Therapy Results in the Real World Practice in the Czech Republic NCT01055977	AstraZeneca	—
Completed	Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipi NCT00474864	GlaxoSmithKline	Phase 2
Completed	Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome NCT00659321	GWT-TUD GmbH	Phase 3
Completed	GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol NCT00158899	GlaxoSmithKline	Phase 2
Completed	Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP) NCT00653965	AstraZeneca	Phase 3
Completed	Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS) NCT00654225	AstraZeneca	Phase 3
Completed	Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES) NCT00653744	AstraZeneca	Phase 3
Completed	48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety NCT00654602	AstraZeneca	Phase 3